Argenx Targets FDA Label Expansion After Vyvgart Trial Success

Argenx SE (NASDAQ:ARGX) released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab). Part A of the trial randomized participants (1:1) to receive 4 once-weekly infusions of efgartigimod IV or placebo, followed by a 5-week follow-up and primary…